Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
about
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.PTEN regulates BCRP/ABCG2 and the side population through the PI3K/Akt pathway in chronic myeloid leukemiaPhase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizatiStrategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia.Dynamics and potential impact of the immune response to chronic myelogenous leukemiaResults of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission.Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.Interpreting molecular monitoring results and international standardization in chronic myeloid leukemia.High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemiaPrediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance.Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based reviewThe achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure.Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapyKinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaChronic Myelogenous Leukemia, Version 1.2014Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.Interpretation of cytogenetic and molecular results in patients treated for CML.Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulatinSignificance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?Establishment of a standardized multiplex assay with the analytical performance required for quantitative measurement of BCR-ABL1 on the international reporting scale.The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitorsBCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays.Suboptimal responses in chronic myeloid leukemia: implications and management strategiesMonitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase - the importance of a major molecular response
P2860
Q27851450-BFF356D3-1A96-44AC-A480-0FB377002F46Q28540547-FCC36BCD-EEC9-4263-85D1-F50E88AED117Q30357011-792385AE-0D65-49DC-B00A-DE86DB2D18FAQ30984215-C7A1C783-25A2-4D39-967D-F11019EC1C69Q33345245-518DE80E-C19C-4293-B0E6-698390C906E8Q33387517-B9E95D07-A1E3-49B3-9E1C-620246D8B3D5Q33387519-BF9CA8DF-EFF9-469D-A2AB-D54D20275D25Q33398716-255A8440-FEF2-412D-ABF0-B6C3FCB5F2DAQ33561227-1ACD653A-95D3-4CBC-8662-D0D40FA62D7BQ33561232-E7778A53-CC4A-40CE-8530-1338719F3FA2Q33750753-C13FD840-28A4-454D-B025-114B827A94EDQ33843731-E72C7D20-9E29-49E3-AA05-50A5CF67CB67Q33844041-24C0A2AB-58C8-4A89-BCBA-17BE722B6DF8Q33844109-557BE908-E840-4C88-B328-6C59196800F7Q33885583-6F6BF7C0-E313-433F-9634-C23DCC5BC96EQ33886162-D42D88D2-B7F4-429C-A1C4-133D852E3134Q33886167-48E6976D-FCD7-418C-A3A4-7A7D9E706E95Q34073579-0E837AEA-6841-4254-9529-6CD45FFACDC9Q34130343-8E5CDA3D-1998-44EB-9770-7E3869ACAA2CQ34163101-D40E6875-080F-4808-A15C-1532201F2596Q34293384-9B42DD03-183A-4654-866C-FD022FE0CE0AQ34293414-27CF65C9-0648-4C2B-948D-DA3C7BC59680Q34297594-F05206DB-C539-4AFB-8E76-9C66F78998E1Q34302673-F1A649A6-7FFA-40A0-9368-D7B91E9A0225Q34378360-746D3ED7-1D4A-4556-9237-74CE97CC0267Q34522789-ACCA60CA-DFD6-4FB1-9DF8-1ED74954811AQ34522810-F5893110-9DA6-4815-913B-3FBB7403C00DQ34763374-3D8563E7-9762-4B19-8996-C3DCC48E8B98Q34765448-901A259A-EB13-47E4-B65F-09166B186BE1Q35034528-DEF5D0D8-CB33-4637-8573-BD13E6F094A7Q35300745-D6DECD19-12C5-4B9F-A4E8-C74CC1345E41Q35565658-CAA20670-3464-4882-8077-96416106C20CQ35664358-A5F3E0E2-FB24-45B5-A534-D2D21E85870FQ35794115-E0797F64-BB58-4C6E-B23B-55173E4ED0B2Q35849671-A54F9A4F-21BF-412F-B287-1D0D8A192DFEQ35849776-D94F6F3E-5E70-4DD6-8DB3-0D9C96622592Q35995232-38BDFC9E-D639-4416-984A-0CA7E2499D77Q35998184-D25020F1-6C78-49FA-8F7C-E36D93831CDCQ36144079-417F8E57-7B1D-4EC0-98E0-27F6E24F9981Q36153509-0B2AAD03-793F-4A3E-B33E-68AB85169E94
P2860
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Molecular responses in patient ...... reated with imatinib mesylate.
@en
type
label
Molecular responses in patient ...... reated with imatinib mesylate.
@en
prefLabel
Molecular responses in patient ...... reated with imatinib mesylate.
@en
P2093
P50
P1476
Molecular responses in patient ...... reated with imatinib mesylate.
@en
P2093
Jenny Shan
Moshe Talpaz
Rajyalakshmi Luthra
P304
P356
10.1158/1078-0432.CCR-04-2139
P407
P50
P577
2005-05-01T00:00:00Z